Day One Biopharmaceuticals, Inc.
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | Kinase InhibitorSmall molecule | Glioma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
May 2027 (1)
Est. primary completion 2027-05-31 · NCT04775485 · CT.gov ↗
What to watch
June 2027 (1)
TovorafenibPhase 3Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Est. primary completion 2027-06 · NCT05566795 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.